from the management page of Biota's website.
If he is no longer with the company, then that excises all Australian senior connections with the company, with the exception of Jim Fox.
There are still a great number of Australian based shareholders who hold a significant number of shares. What an odd situation to have arrived at, although there were people present at the meeting to vote on the Nasdaq move who predicted this outcome.
I don't think it matters much though, does it? Don't recall being frequently overjoyed by the decisions of mgt in Australia. What does matter is that the present mgt do everything humanly possible to turn this story around. A deal with a US major to bring LANI to the ROW markets quickly - and at a royalty rate of around 40% - 50% of net sales.
ReplyDeleteFair enough.
ReplyDeleteLet's see what tonight's announcement brings. If there's no Inavir partnering deal included, I can't see how any further trials can start before this Northern winter. I thought that they might have spoken to FDA about the BARDA funded trials by now.
I'll also be interested to see if anyone asks any questions, rather than the one Guggenheim guy who never seems that interested.
Maybe one of us should call in to ask about the Relenza patent issue and the Inavir partnering question.